AU Patent

AU2015355220B2 — Combinations for the treatment of neuroblastoma

Assigned to Ignyta Inc · Expires 2020-02-27 · 6y expired

What this patent protects

Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.

USPTO Abstract

Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015355220B2
Jurisdiction
AU
Classification
—
Expires
2020-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Ignyta Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.